Dydo Pharma

Executive Summary

Dydo Pharma, based in Osaka, Japan, is a private pharmaceutical company dedicated to developing small molecule therapies for rare neurological disorders. The company's lead product, Firdapse® (amifampridine phosphate), received regulatory approval in Japan for Lambert-Eaton myasthenic syndrome (LEMS), marking a key commercial milestone. With a focused portfolio and emphasis on strategic collaborations, Dydo Pharma leverages partnerships to enhance R&D and commercialization capabilities across various fields. The company operates with a lean team of 10-50 employees and targets underserved patient populations in the neurology space.

Upcoming Catalysts (preview)

• Q3 2026Firdapse Launch in Additional Asian Markets60% success
• Q4 2026New Indication Filing for Firdapse (e.g., congenital myasthenic syndromes)40% success
• TBDStrategic Partnership for Pipeline Expansion70% success